Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
March 12, 2001
- Over 90% of Nursing Staff Have Committed or Nearly Committed Errors
March 12, 2001
- Japan Tobacco to Make Pharma Business Profitable in FY2005
March 12, 2001
- Strategic Value of Product Forecasting Is Critical: Dr Ramsey of Mattson Jack Group
March 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 12, 2001
- Dainippon to Report Record-high Sales, Profits Again: President Miyatake
March 12, 2001
- Chugai Forms Functional Genomics Alliance with Immusol
March 12, 2001
- Domestic Market for CRO Business Estimated to Be \150 Bil.: CMIC President
March 12, 2001
- Next-generation Vitamin D Expected to Be Effective for Colon Cancer: Chugai Seminar
March 12, 2001
- IFPMA Creates Task Force on Access to Anti-AIDS Drugs
March 12, 2001
- AstraZeneca to Launch 3 New Drugs per Year in All Major Markets
March 5, 2001
- Large Intervention Study on Hypertension Targets 9,000 Patients in Japan
March 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 5, 2001
- Korosho to Deal with Biologics in Earnest
March 5, 2001
- Korosho to Issue GL Regarding NAT for HBV, HCV, HIV
March 5, 2001
- JPMA Invites Participation in Protein Structure Analysis Consortium
March 5, 2001
- 39 New Drugs Approved in 2000: PMSB
March 5, 2001
- Individual Health Insurance Cards to Be Introduced in April
March 5, 2001
- JPMA Calls For Maintenance of NHI Price Listing by Brand Name
March 5, 2001
- GL for Investigational Use of ES Cells Proposed
March 5, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…